|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages显示文摘How the innate and adaptive host immune system miscommunicate to worsen COVID-19 immunopathology has not been fully elucidated.Here,we perform single-cell deep-immune profiling of bronchoalveolar lavage(BAL)samples from 5 patients with mild and 26 with critical COVID-19 in comparison to BALs from non-COVID-19 pneumonia and normal lung.We use pseudotime inference to build T-cell and monocyte-to-macrophage trajectories and model gene expression changes along them.In mild COVID-19,CD8^(+)resident-memory(TRM)and CD4^(+)T-helper-17(T_(H17))cells undergo active(presumably antigen-driven)expansion towards the end of the trajectory,and are characterized by good effector functions,while in critical COVID-19 they remain more naïve.Vice versa,CD4^(+)T-cells with T-helper-1 characteristics(TH1-like)and CD8^(+)T-cells expressing exhaustion markers(T_(EX)-like)are enriched halfway their trajectories in mild COVID-19,where they also exhibit good effector functions,while in critical COVID-19 they show evidence of inflammation-associated stress at the end of their trajectories.Monocyte-to-macrophage trajectories show that chronic hyperinflammatory monocytes are enriched in critical COVID-19,while alveolar macrophages,otherwise characterized by anti-inflammatory and antigen-presenting characteristics,are depleted.In critical COVID-19,monocytes contribute to an ATP-purinergic signaling-inflammasome footprint that could enable COVID-19 associated fibrosis and worsen disease-severity.Finally,viral RNA-tracking reveals infected lung epithelial cells,and a significant proportion of neutrophils and macrophages that are involved in viral clearance. | Els Wauters Pierre Van Mol Abhishek Dinkarnath Garg Sander Jansen Yannick Van Herck Lore Vanderbeke Ayse Bassez Bram Boeckx Bert Malengier-Devlies Anna Timmerman Thomas Van Brussel Tina Van Buyten Rogier Schepers Elisabeth Heylen Dieter Dauwe Christophe Dooms Jan Gunst Greet Hermans Philippe Meersseman Dries Testelmans Jonas Yserbyt Sabine Tejpar Walter De Wever Patrick Matthys CONTAGIOUS collaborators Johan Neyts Joost Wauters Junbin Qian Diether Lambrechts | 2021 | Cell Research2021，31，3： | 11 |
| 2 | Coxsackievirus mutants that can bypass host factor PI4KIIIβ and the need for high levels of PI4P lipids for replication显示文摘 | Hilde M van der Schaar Lonneke van der Linden Kjerstin H W Lanke Jeroen R P M Strating Gerhard Purstinger Erik de Vries Cornelis A M de Haan Johan Neyts Frank J M van Kuppeveld | 2012 | Cell Research2012，22，11： | 3 |
| 3 | 显示文摘 | Neyts Johan | 2006 | J Med Chem2006，49，： | 1 |
| 4 | Antiviral treatment of chronic hepatitis B virus infections : the past, the present and the future显示文摘 | Geoffrey F e rir Suzanne Kaptein Johan Neyts | 2008 | Revi Med Virol2008，18，1： | 1 |
| 5 | Hepatitis C Virus Infection of Neuroepithelioma Cell Lines显示文摘 | Nicola F. Fletcher Jian Ping Yang Michelle J. Farquhar Ke Hu Christopher Davis Qiuchen He Kimberly Dowd Stuart C. Ray Sophie E. Krieger Johan Neyts Thomas F. Baumert Peter Balfe Jane A. McKeating Flossie Wong–Staal | 2010 | Gastroenterology2010，，4： | 1 |
| 6 | Inhibition of Urokinase-Type Plasminogen Activator or Matrix Metalloproteinases Prevents Cardiac Injury and Dysfunction During Viral Myocarditis显示文摘 | Stephane Heymans Matthias Pauschinger Armando De Palma Angela Kallwellis-Opara Susanne Rutschow Melissa Swinnen Davy Vanhoutte Fangye Gao Raimund Torpai Andrew H. Baker Elisabeth Padalko Johan Neyts Heinz-Peter Schultheiss Frans Van de Werf Peter Carmelie | 2006 | Circulation2006，，6： | 1 |
| 7 | Human pluripotent stem cell-derived hepatocytes support complete replication of hepatitis C virus显示文摘 | Philip Roelandt Susan Obeid Jan Paeshuyse Jolien Vanhove Alfons Van Lommel Yaakov Nahmias Frederik Nevens Johan Neyts Catherine M Verfaillie | 2012 | Journal of Hepatology2012，，2： | 1 |
| 8 | A ease for developing antiviral drugs against polio显示文摘 | Marc S Collett Johan Neyts | 2008 | Antiviral Research2008，79，： | 1 |
| 9 | Calcineurin Inhibitors Stimulate and Mycophenolic Acid Inhibits Replication of Hepatitis E Virus显示文摘 | Yijin Wang Xinying Zhou Yannick Debing Kan Chen Luc J W Van der laan Johan Neyts Harry L A Janssen Herold J. Metselaar Maikel P. Peppelenbosch Qiuwei Pan | 2014 | Gastroenterology2014，，： | 1 |
| 10 | Hepatitis B virus replication causes oxidative stress in HepAD38 liver cells显示文摘 | Tamara Severi Chunxiao Ying Joris Robert Vermeesch David Cassiman Lieselotte Cnops Chris Verslype Johan Fevery Lutgarde Arckens Johan Neyts Jos F. Pelt PhD Ing | 2006 | Molecular and Cellular Biochemistry (-)2006，，1： | 1 |
| 11 | Spiro[pyrrolidine-2,2′-adamantanes]: synthesis, anti-influenza virus activity and conformational properties显示文摘 | Ioannis Stylianakis Antonios Kolocouris Nicolas Kolocouris George Fytas George B Foscolos Elizaveta Padalko Johan Neyts Erik De Clercq | 2003 | Bioorganic & Medicinal Chemistry Letters2003，，10： | 1 |
| 12 | Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors显示文摘The main protease(M^(pro))of SARS-CoV-2 is an attractive target in anti-COVID-19 therapy for its high conservation and major role in the virus life cycle.The covalent M^(pro)inhibitor nirmatrelvir(in combination with ritonavir,a pharmacokinetic enhancer)and the non-covalent inhibitor ensitrelvir have shown efficacy in clinical trials and have been approved for therapeutic use.Effective antiviral drugs are needed to fight the pandemic,while non-covalent M^(pro)inhibitors could be promising alternatives due to their high selectivity and favorable druggability.Numerous non-covalent M^(pro)inhibitors with desirable properties have been developed based on available crystal structures of M^(pro).In this article,we describe medicinal chemistry strategies applied for the discovery and optimization of non-covalent M^(pro)inhibitors,followed by a general overview and critical analysis of the available information.Prospective viewpoints and insights into current strategies for the development of non-covalent M^(pro)inhibitors are also discussed. | Letian Song Shenghua Gao Bing Ye Mianling Yang Yusen Cheng Dongwei Kang Fan Yi Jin-Peng Sun Luis Menéndez-Arias Johan Neyts Xinyong Liu Peng Zhan | 2024 | Acta Pharmaceutica Sinica B2024，14，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员